Browse Neurology Articles by Topic

The Effect of High-Dose Vitamin D on Clinically Isolated Syndrome and MS

This study by Thouvenot et al evaluated the effectiveness of high-dose vitamin D treatment on clinically isolated syndrome and early multiple sclerosis as monotherapy and reported a reduced incidence of new disease activity compared to the control group.

Can Anti-Amyloid Antibody Treatment Delay the Clinical Onset of Alzheimer’s Disease?

In this open-label extension of the dominantly inherited Alzheimer’s disease gantenerumab trial (DIAN-TU), long-term continuous amyloid clearance over eight or more years in asymptomatic carriers of autosomal dominant Alzheimer’s mutations showed potential to delay symptom onset and slow progression. Shorter duration or partial clearance did not yield measurable clinical benefit, suggesting that only sustained, near-complete amyloid removal may have disease-modifying effects.

Manual Maneuvers for the Treatment of Benign Positional Vertigo

Benign positional vertigo is a challenge to treat. This clinical trial from investigators in South Korea demonstrated modest efficacy in resolving posterior canal-related vertigo with a head-shaking maneuver that is easily performed in an office setting.

Long-Term NSAID Use May Lower Dementia Risk

In a prospective population-based study of nonsteroidal anti-inflammatory drugs, long-term use was associated with a reduced risk for dementia compared with short- and intermediate-term use.

Clinical Consequences of Alzheimer’s and Lewy Body Co-Pathologies

This large study of patients with cognitive impairment-assessed cerebrospinal fluid biomarkers, positron emission tomography imaging, and cognitive tests showed that those with evidence of both Alzheimer’s and Lewy body pathologies had greater cognitive dysfunction and faster progression than those with either pathology alone.

Apomorphine Hydrochloride Injection (Onapgo)

The U.S. Food and Drug Administration has approved apomorphine as a constant subcutaneous infusion for the treatment of advanced Parkinson’s disease with persistent motor fluctuations. It is the second subcutaneous infusion for this indication following foscarbidopa/foslevodopa (as Vyalev).

Determinants of Long-Term Outcome After Concussion

This cohort study of U.S. veterans found that mild traumatic brain injuries occurring alongside psychological trauma are associated with long-term post-concussive symptoms and disability. The authors postulate that the traumatic context contributes to the development of post-traumatic stress disorder, which may in turn potentiate long-term sequelae.

Stroke 2025 Is Here!

Stroke 2025: Optimizing Outcomes with Clinical Approaches provides evidence-based, cutting edge, clinical information on treating stroke and other neurological problems in a concise, accurate, and clinically relevant format. Written and edited by leading experts in the fields of neurology and emergency medicine, Stroke 2025 is an unbiased resource for any physician or nurse working in an emergency department or stroke center. Healthcare providers can earn all of the Joint Commission-required stroke credits at one time through this electronic publication.

Clinical Consequences of Alzheimer’s and Lewy Body Co-Pathologies

This large study of patients with cognitive impairment-assessed cerebrospinal fluid biomarkers, positron emission tomography imaging, and cognitive tests showed that those with evidence of both Alzheimer’s and Lewy body pathologies had greater cognitive dysfunction and faster progression than those with either pathology alone.

Long-Term Efficacy of Ocrelizumab as First-Line Treatment for Relapsing-Remitting Multiple Sclerosis

Nine-year follow-up data from open-label extension of the Phase III clinical trials of ocrelizumab show that, although the efficacy of ocrelizumab was maintained throughout the duration of the study, patients who were treated with ocrelizumab from the beginning of the Phase III trials did better than the patients who were on subcutaneous (SC) interferon β-1a initially and were switched to ocrelizumab at the onset of the open-label extension period.